Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 5, 2014, Pages 555-563

  Corneli, Amy ^a   Wang, Meng ^a   Agot, Kawango ^b   Ahmed, Khatija ^c   Lombaard, Johan ^d   Van Damme, Lut ^a,e  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b IMPACT RESEARCH AND DEVELOPMENT ORGANIZATION   (Kenya)

^c Setshaba Research Centre   (South Africa)

^d JOSHA Research   (South Africa)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Adherence; Africa; FEM PrEP; HIV risk perceptions; Pre exposure prophylaxis; Women

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ADENINE; ANTIRETROVIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR DISOPROXIL;

ADULT; CONDOM USE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL (TOPIC); FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PILL; PRIORITY JOURNAL; RISK ASSESSMENT; SEXUAL BEHAVIOR; SEXUALITY; YOUNG ADULT; ADOLESCENT; ANALOGS AND DERIVATIVES; ATTITUDE TO HEALTH; BLOOD ANALYSIS; CHEMOPROPHYLAXIS; DISEASE TRANSMISSION; HIGH RISK BEHAVIOR; HIV INFECTIONS; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION;

ADENINE; ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; BLOOD CHEMICAL ANALYSIS; CHEMOPREVENTION; DEOXYCYTIDINE; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; ORGANOPHOSPHONATES; RISK-TAKING; YOUNG ADULT;

EID: 84925549918     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000362     Document Type: Conference Paper

References (32)

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399-410.
2. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
4. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
5. Marrazzo JM, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir-emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003) [26LB]. Presented at: The 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA.
6. Rosenstock IM. The health belief model and preventive health behavior. Health Educ Behav. 1974;4:354-386.
7. Rogers RW. Cognitive and physiological processes in fear appeals and attitude change: a revised theory of protection motivation. In: Cacioppo JR, Perry RE, eds. Social Psychology: A Sourcebook. New York, NY: Guilford Press; 1983:153-176.
8. Brewer NT, Weinstein ND, Cuite CL, et al. Risk perceptions and their relation to risk behavior. Ann Behav Med. 2004;27:125-130.
9. Brewer NT, Chapman GB, Gibbons FX, et al. Meta-analysis of the relationship between risk perception and health behavior: the example of vaccination. Health Psychol. 2007;26:136-145.
10. Kowalewski MR, Henson KD, Longshore D. Rethinking perceived risk and health behavior: a critical review of HIV prevention research. Health Educ Behav. 1997;24:313-325.
11. Gerrard M, Gibbons FX, Bushman BJ. Relation between perceived vulnerability to HIV and precautionary sexual behavior. Psychol Bull. 1996;119:390-409.
12. Weinstein ND, Nicolich M. Correct and incorrect interpretations of correlations between risk perception and risk behaviors. Health Psychol. 1993;12:235-245.
13. Tenkorang EY, Rajulton F, Maticka-Tynadle E. Perceived risks of HIV/AIDS and first sexual intercourse among youth in Cape Town, South Africa. AIDS Behav. 2009;13:234-245.
14. Do M, Meekers D. Multiple sex partners and perceived risk of HIV infection in Zambia: attitudinal determinants and gender differences. AIDS Care. 2009;21:1211-1221.
15. Bradley H, Tsui A, Hindin M, et al. Developing scales to measure perceived HIV risk and vulnerability among Ethiopian women testing for HIV. AIDS Care. 2011;23:1043-1052.
16. Macintyre K, Rutenberg N, Brown L, et al. Understanding perceptions of HIV risk among adolescents in KwaZulu-Natal. AIDS Behav. 2004;8:237-250.
17. Majaraj P, Cleland J. Risk perception and condom use among married or cohabiting couples in KwaZulu-Natal, South Africa. Int Fam Plan Perspect. 2005;31:24-29.
18. Stringer EM, Sinkala M, Kumwenda R, et al. Personal risk perception, HIV knowledge and risk avoidance behavior, and their relationship to actual HIV serostatus in an urban African obstetric population. J Acquir Immune Defic Syndr. 2004;35:60-66.
19. Akwara PA, Madise NJ, Hinde A. Perception of risk of HIV/AIDS and sexual behaviour in Kenya. J Biosoc Sci. 2003;35:385-411.
20. Mbizvo EM, Msuya SE, Hussain A, et al. HIV prevalence in Zimbabwean women: 54-67% knowledge and perceived risk. Int J STD AIDS. 2003;14:202-207.
21. FHI360. Press release: FHI to initiate orderly closure of FEM-PrEP. April 18, 2011. Available at: www.fhi360.org/fhi-statement-fem-prep-hivprevention-study. Accessed May 1, 2014.
22. Corneli AL, Deese J, Wang M, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily, oral study product for preexposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66:324-331.
23. Waters EA, McQueen A, Cameron LD. Perceived risk and its relationship to health-related decisions and behavior. In: Martin LR, DiMatteo MR, eds. The Oxford Handbook of Health Communication, Behavior Change, and Treatment Adherence. New York, NY: Oxford University Press; 2014:193-213.
24. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra125.
25. Adams JL, Sykes C, Menezes P, et al. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? J Acquir Immune Defic Syndr. 2013;62:260-266.
26. SAS. Version 9.2. Cary, NC: SAS Institute, Inc; 2009.
27. Aaron E, Cohan D. Preexposure prophylaxis for the prevention of HIV transmission to women. AIDS. 2013;27:F1-F5.
28. Headley J, Lemons A, Corneli A, et al. The sexual risk context among the FEM-PrEP study population in Bondo, Kenya and Pretoria, South Africa. PLoS One. 2014;9:e10641.
29. Corneli A, McKenna K, Headley J, et al. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEMPrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. J Int AIDS Soc. 2014;17:19152.
30. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10:e1001511.
31. Ware NC, Wyatt MA, Haberer JE, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59:463-468.
32. Windschitl PD. Measuring and conceptualizing: perceptions of vulnerability/likelihood. Presented at: The Conceptualizing and Measuring Risk Perceptions Workshop; February 13-14, 2003; Washington, DC.